Optimizing the Management of High-Risk ACS Patients: Exploring Antiplatelet Approaches to Improve Patient Outcomes

Cardiology
Curriculum:
Managing high-risk patients wtih ACS
Credits:
1 AMA PRA Category 1 Credits
Launch Date:
31-Jul-14
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Cardiologists, Internal Medicine Physicians, Emergency Room Clinicians, And Other Health Care Professionals Involved In The Treatment Of Acs

Relevant Terms:

Myocardial Infarction, Thrombosis, Anticoagulant Therapy

Dominick J. Angiolillo, MD, PhD

Dominick J. Angiolillo, MD, PhD
Associate Professor of Medicine
Director, Cardiovascular Research
University of Florida College of Medicine-Jacksonville
Division of Cardiology
Jacksonville, FL

Dominick J. Angiolillo, MD, PhD is an Associate Professor of Medicine with Tenure Status and the Director of Cardiovascular Research at the University of Florida College of Medicine (UFCM) in Jacksonville, FL. He also serves as the Director of the Center for Thrombosis Research at UFCM, and as an Invited Professor in Cardiology at the University of Catania in Italy. Dr. Angiolillo is a member of the Institutional Review Board at UFCM and serves as faculty for the American College of Cardiology Interventional Cardiology Board Review Course.
 
Dr. Angiolillo is a Fellow of the American College of Cardiology, European Society of Cardiology, and Society for Cardiac Angiography and Interventions. He received his medical degree from Catholic University of the Sacred Hearth Medical School in Rome, Italy, where he also completed a PhD in molecular and cellular cardiology at Catholic University of the Sacred Hearth Medical School, and in interventional cardiology at Complutense University in Madrid, Spain. He is a member of numerous professional societies, committees, boards, and working groups, and has authored or co-authored close to 300 articles in peer-reviewed journals and other medical publications.
 
Presenter of more than 350 abstracts at major national and international scientific meetings, Dr. Angiolillo has been a frequent invited faculty member and lecturer at meetings and conferences of the American Heart Association, American College of Cardiology, European Society of Cardiology, Society of Cardiac Angiography and Cardiac Interventions, Transcatheter Cardiovascular Therapeutics, World Congress on Heart Disease, and the Euro PCR. He has conducted research for investigator-initiated, industry-funded, and sponsored research for more than a decade in vascular biology, coronary artery disease, acute coronary syndrome, intravascular imaging, cardiovascular antithrombotic pharmacotherapy, and other areas of cardiology and interventional cardiology.

Stephen D. Wiviott, MD, FACC

Stephen D. Wiviott, MD, FACC
Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, MA

Stephen D. Wiviott, MD, FACC is is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) in 1990 and Harvard Medical School (Honors) in 1996. He served as a Medical House Officer and Chief Medical Resident at Brigham and Women's Hospital. Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women's Hospital. After completion of his training, he joined the faculty of the Cardiovascular Division of Brigham and Women's Hospital and serves as Associate Professor of Medicine at Harvard Medical School, as well as a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group. He also attends in the Lown Cardiovascular Intensive Care Unit at Brigham and Women's Hospital. 
 
As a Senior Investigator with the TIMI Study Group, Dr. Wiviott has played important roles in the planning, implementation, and interpretation of several multicenter, national, and international clinical trials in ACS and studying antiplatelet therapies. He has played leadership roles in the JUMBO-TIMI 26 trial and the TRITON-TIMI 38 trial, the major phase II and III trials of prasugrel. He was the Principal Investigator of PRINCIPLE-TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI, and of the TIMI 38 Coronary Stent Registry, an ongoing international registry of the long-term outcomes of patients receiving different types of intracoronary stents for acute coronary syndromes. He is the Chairman of the TIMI Clinical Events Committee.
 
Dr. Wiviott is an author of more than 100 peer-reviewed publications in major medical and cardiovascular journals and of multiple chapters in major cardiovascular textbooks, including Cardiovascular Therapeutics, a companion to Braunwald's Heart Disease. He has delivered local, national, and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, and anticoagulants. Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, cholesterol-lowering therapy, and secondary prevention of CAD.
1. Identify high-risk ACS patients (high-risk NSTEMI, STEMI) and promptly initiate suitable risk stratification and patient management strategies
2. Adopt and adhere to guidelines-based treatment strategies for use of appropriate antiplatelet options to reduce the risk of recurrent events
3. Identify inefficiencies in discharge planning and patient education on the necessity of drug adherence to improve quality of care and long-term outcomes of high-risk ACS patients

DISCLOSURE POLICY STATEMENT
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
 
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
 
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
 
Faculty Disclosures
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
 
Stephen D. Wiviott, MD, FACC:  Consultant: Daiichi-Sankyo, Eli Lilly, ICON, Johnson & Johnson, St. Jude Medical; Research: AstraZeneca, Eisai, Merck
                                                                                             
Dominick J. Angiolillo, MD, PhD: Advisory Board: Abbott Vascular, AstraZeneca, Bristol-Myers Squibb/Sanofi-Aventis, Eli Lilly/Daiichi-Sankyo, The Medicines Company, Merck; Data Safety Monitoring Board: Johnson & Johnson, St. Jude Medical, Sunovion; Research: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Esther and King Biomedical Research, Evolva, Gilead, Johnson & Johnson, The Medicines Company; Speaker: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Merck
                                                      
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Blair St. Amand; Jay Katz, CCMEP; Laurie Muldowney, MD:
Nothing to disclose
 
DISCLOSURE ATTESTATION
 
DISCLAIMER
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
 
CREDIT DESIGNATION
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

PROVIDERSHIP
This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.

COMMERCIAL SUPPORT
This program is supported through an educational grant from Daiichi-Sankyo, Inc. and Lilly USA, LLC.
 
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
 

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above